(Q28212376)

English

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

scientific article (publication date: 2002)

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer (English)

0 references

1 reference

1 reference

F Caponigro

1

0 references

C Dittrich

series ordinal

2

0 references

J B Sorensen

series ordinal

3

0 references

J H M Schellens

series ordinal

4

0 references

F Duffaud

series ordinal

5

0 references

L Paz Ares

series ordinal

6

0 references

D Lacombe

series ordinal

7

0 references

C de Balincourt

series ordinal

8

0 references

P Fumoleau

series ordinal

9

0 references

language of work or name

English

0 references

publication date

January 2002

0 references

published in

European Journal of Cancer

0 references

volume

38

0 references

page(s)

70-4

0 references

issue

1

0 references

cites work

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900336-7

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900336-7

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900336-7

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900336-7

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900336-7

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

A special role for amsacrine in the treatment of acute leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900336-7

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900336-7

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1016/S0959-8049(01)00336-7

0 references

PubMed ID

11750842

0 references

(Q28212376)

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)